Investment
Features
FeesSafety
Academy
More
Pluang+

Regeneron's melanoma drug trial fails to outperform Merck's Keytruda, shares drop sharply.

Market News
18 May 2026
Barrons
View Source
Bearish
pluang ai news

Regeneron Pharmaceuticals reported that its late-stage trial for the skin cancer drug fianlimab did not meet the primary endpoint, failing to outperform Merck's Keytruda. This setback caused Regeneron's stock to fall significantly in premarket trading and led to multiple analyst downgrades on Wall Street. The trial's failure raises questions about the drug's future prospects and could impact Regeneron's position in the competitive melanoma treatment market.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App